TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06350474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of dornase alfa (Dnase)
Description: Discontinuation of current dornase alfa (Dnase) therapy during 6-week study period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of dornase alfa (Dnase)
Description: Continuation of current dornase alfa (dnase) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily)
Study: NCT04268550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Given PO
Study: NCT02675114

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SAVR
Description: SAVR with a commercially available bioprosthetic valve.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 THV
Description: TAVR with the Edwards SAPIEN 3 Transcatheter Heart Valve and Edwards Commander Delivery System
Study: NCT01496976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Methylprednisolone (HDMP)
Description: HDMP will be administered at 1 gm/m\^2 IV over 90 minutes daily with ofatumumab infusions 1-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab infusion will be administered immediately after HDMP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: The Lenalidomide Starting Dose (Cycle 4) Based on Renal Function Prior to Cycle 4 of Treatment.
Study: NCT02546115

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tension night splint
Description: this is the use of a commercially available tension night splint device, to be worn by the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard practice - a structured rehabilitation programme
Description: this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard practice - a structured rehabilitation programme
Description: this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves
Study: NCT01702831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Once daily intravenous (IV) busulfan at a dose of 3.2 mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -5 to -3), option 1 OR Once daily intravenous (IV) busulfan at a dose of 3.2mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -6 to -4), option 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: I.V. reduced dose of melphalan (140mg/m2) on day -2, followed by an autologous stem cell transplant on day 0 (day -1 will be a rest day) - this is referred to as Option 1 dosing schema OR I.V. reduced dose of melphalan (140mg/m2) on day -3 followed by autologous stem cell transplant on day 0 (days -2 and -1 will be rest days). This is referred to as Option 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral lenalidomide 10mg per day (on all 28 days of a 28 day cycle) for the first three cycles and then escalated to 15 mg daily if clinically appropriate to do so. The lenalidomide maintenance will start on day 100 post ASCT and continue till disease progression.
Study: NCT03550885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High taurine and saturated fat diet
Description: This is a 3-week (21 day) isocaloric Western-type diet with all meals, snacks, beverages and condiments provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low in taurine and saturated fat diet
Description: This is a 3-week (21 day) isocaloric largely plant-based diet with all meals, snacks, beverages and condiments provided.
Study: NCT01343927

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly yoga classes
Description: Manualized 12-week Hatha yoga intervention developed specifically for chronic low back pain in adult populations; classes meet once each week at community-based locations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual physical therapy treatment
Description: 12 weeks of fifteen individual physical therapy sessions divided as follows: Week 1 intake appointment; weeks 2-4 two appointments per week; weeks 5-12 one appointment per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants given The Back Pain Helpbook and periodic newsletters addressing back pain and self care.
Study: NCT02026960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RNA extraction and amplification from biopsy specimens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RNA extraction and amplification from biopsy specimens
Study: NCT03939156

Intervention type: OTHER
Intervention: Completion of questionnaires
Description: Completion of questionnaires at the time of study entry

Intervention type: OTHER
Intervention: Completion of questionnaires
Description: Completion of questionnaires at the time of study entry

Intervention type: OTHER
Intervention: Completion of questionnaires
Description: Completion of questionnaires at the time of study entry
Study: NCT03152032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-House Vocational Training Programs
Description: At the beginning of the IHVT programs, the job placement for each participant was determined jointly by the participant's interest, the demands of local job markets and the team evaluation. The programs covered 6 to 10 months in length, 5 days a week and 4 to 6 hours a day. The programs contained three sessions: (a) the work-related behavior training session, such as proper appearance, communication and self assertion, and workplace social skills, (b) the on-the-job skill training session where participants gained job-specific training and interventions from job coaches and occupational therapists, and (c) the life balance counseling session including individual and group counseling that aimed to enhance the participants' ability to tackle potential hardships and barriers to work.
Study: NCT04233034

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HCL
Description: Hybrid Closed Loop therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HCL
Description: Hybrid Closed Loop therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verapamil 120mg tablet
Description: verapamil tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verapamil 120mg tablet
Description: verapamil tablet

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: non-HCL
Description: Usual diabetes care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-HCL
Description: Usual diabetes care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo pill manufactured to mimic verapamil 120mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pill manufactured to mimic verapamil 120mg tablet
Study: NCT02135159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM1
Description: administration of the TDM1 by IV perfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM1
Description: administration of the TDM1 by IV perfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM1
Description: administration of the TDM1 by IV perfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM1
Description: administration of the TDM1 by IV perfusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain Sequential RT
Description: local RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain Sequential RT
Description: local RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain Sequential RT
Description: local RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain Sequential RT
Description: local RT
Study: NCT02360215

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole brain radiation therapy with hippocampal avoidance
Description: Intensity modulated radiation therapy (IMRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately two week; starting within 21 calendar days after randomization.
Study: NCT01471262

Intervention type: PROCEDURE
Intervention: Extended right hepatectomy
Description: Right hepatectomy involving 5 or more segments

Intervention type: PROCEDURE
Intervention: Extended right hepatectomy
Description: Right hepatectomy involving 5 or more segments
Study: NCT03768245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education and Physical activity program
Description: Its objective is to empower children on healthy lifestyle, addressing four main topics: nutrition (i.e. healthy food, hydration), adequate quantities of food, physical activity, and self-monitoring. The program is implemented in the classroom through workshops planned and conducted by psychologists and nutritionists. A total of 12 workshops are planned, to be conducted once a week, and lasting 50 minutes each. The Physical activity program objective is to develop an active scholar environment, and consists of a moderate-vigorous activity, five days a week. The activities are divided into two types: (a) in the school backyard for 60 minutes, three times a week, and (b) in the classroom two days a week, for 15 minutes three times a day, adding up to 45 minutes daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education and Physical activity program
Description: Its objective is to empower children on healthy lifestyle, addressing four main topics: nutrition (i.e. healthy food, hydration), adequate quantities of food, physical activity, and self-monitoring. The program is implemented in the classroom through workshops planned and conducted by psychologists and nutritionists. A total of 12 workshops are planned, to be conducted once a week, and lasting 50 minutes each. The Physical activity program objective is to develop an active scholar environment, and consists of a moderate-vigorous activity, five days a week. The activities are divided into two types: (a) in the school backyard for 60 minutes, three times a week, and (b) in the classroom two days a week, for 15 minutes three times a day, adding up to 45 minutes daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Program
Description: Its objective is to maintain lean mass, decrease fat mass and ensure mineral vitamins and fatty acids intake, maintain proper growth under National Specific Action Program: Food and Activity4. From total energy, a fat intake of 25-35%, carbohydrate intake of 45-65%, protein intake of 10-30%, and total calories are adjusted according to age. The Nutrition program consists of three meals: breakfast, a snack for a mid-morning playtime, and lunch at school. Food is prepared daily following sanitary and quality standards of Mexican official regulation. Breakfast is served 40 minutes before starting class time, lunch is served 40 minutes before leaving school.
Study: NCT02360215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Given PO daily during and after radiation therapy for a total of 24 weeks. Week 1: 5 mg in the AM, none in the PM; Week 2: 5 mg in the AM, 5 mg in the PM; Week 3: 10 mg in the AM, 5 mg in the PM; Weeks 4-24: 10 mg in the AM, 10 mg in the PM. Should start the same day as radiation therapy, at latest before the fourth radiation treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Given PO daily during and after radiation therapy for a total of 24 weeks. Week 1: 5 mg in the AM, none in the PM; Week 2: 5 mg in the AM, 5 mg in the PM; Week 3: 10 mg in the AM, 5 mg in the PM; Weeks 4-24: 10 mg in the AM, 10 mg in the PM. Should start the same day as radiation therapy, at latest before the fourth radiation treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole brain radiation therapy
Description: Whole brain radiation therapy (WBRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately 2 weeks
Study: NCT00562627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: intraoperative and 1. postoperative day
Study: NCT04158687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-692
Description: Administered as powder for oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-692
Description: Administered as powder for oral solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as powder for oral solution.
Study: NCT01217580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Description: 20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: 20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
Study: NCT01660295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certoparin 3,000 IU Once Daily
Description: Certoparin 3,000 IU subcutaneous injection once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certoparin 3,000 IU Once Daily
Description: Certoparin 3,000 IU subcutaneous injection once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certoparin 3,000 IU Twice a Day
Description: Certoparin 3,000 IU subcutaneous injection twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certoparin 8,000 IU Once Daily
Description: Certoparin 8,000 IU subcutaneous injection once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certoparin 8,000 IU Twice a Day
Description: Certoparin 8,000 IU subcutaneous injection twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certoparin 8,000 IU Twice a Day
Description: Certoparin 8,000 IU subcutaneous injection twice a day
Study: NCT00624104

Intervention type: DIETARY_SUPPLEMENT
Intervention: Food (fat free meal)
Description: Fat free meal (40% of REE)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Food (fat free meal)
Description: Fat free meal (40% of REE)
Study: NCT00562627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adrenaline
Description: intraoperative LIA (IV and IA) and continuous EDA
Study: NCT00406809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.
Study: NCT00562627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenaline
Description: intraoperative LIA (IV and IA) and continuous EDA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenaline
Description: intraoperative LIA (IV and IA) and continuous EDA
Study: NCT00406809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.
Study: NCT02595307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pamphlet
Description: Written pamphlet outlining the risks of surgery as discussed in consultation.
Study: NCT00038792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Keratinocyte Growth Factor
Study: NCT00550472

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus 74-2 Bifidobacterium animalis subsp. lactis DGCC 420
Study: NCT04907448

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: The IsoK-ST group received their usual physical therapy program for 45 minutes, three times a week for eight successive weeks, which comprised advanced balance training, weight-bearing exercises, gait training, postural and flexibility exercises, and strength training exercises.~Additionally, the IsoK-ST group received an IsoK-ST program, thrice/week for eight successive weeks.~The control group received the usual physical rehabilitation program only for 45 minutes, three times a week for eight successive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The IsoK-ST group received their usual physical therapy program for 45 minutes, three times a week for eight successive weeks, which comprised advanced balance training, weight-bearing exercises, gait training, postural and flexibility exercises, and strength training exercises.~Additionally, the IsoK-ST group received an IsoK-ST program, thrice/week for eight successive weeks.~The control group received the usual physical rehabilitation program only for 45 minutes, three times a week for eight successive weeks.
Study: NCT01021878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: icodextrin
Description: glucose sparing dialysis solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dianeal
Description: glucose based dialysis solution
Study: NCT02387203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrevPac (Prevacid, Amoxicillin, Clarithromycin)
Description: 30mg Prevacid, 1g amoxicillin, 500mg clarithromycin administered together for oral use, twice daily for 14 days preoperatively and twice daily for 14 days at least 4 weeks postoperatively
Study: NCT02892409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin capsules
Study: NCT00562627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac
Description: intraoperative and 1. postoperative day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac
Description: intraoperative and 1. postoperative day
Study: NCT02892409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tripotassium bismuth dicitrate
Description: Tripotassium bismuth dicitrate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripotassium bismuth dicitrate
Description: Tripotassium bismuth dicitrate tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets
Study: NCT01876043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plitidepsin
Description: Patients received plitidepsin as an i.v. 3-h infusion of 5 mg/m2/day on days 1 and 15 every 4 weeks. Patients discontinued plitidepsin if one of the following occurred: consent withdrawal, unacceptable toxicity, disease progression (RECIST v1.1), intercurrent illness or investigator's decision.~Single-arm phase II clinical trial based on a two-stage optimal Simon's design with 37 evaluable patients (first stage: 17 patients) used to distinguish a favorable true non-progression rate of 40% from a null rate of 20% (90% power and 10% type I error).~* Stage 1(17 participants): if \<=3 non-progressions at 3 months, the study was stopped early. Otherwise, the second group of 20 participants was recruited.~* Stage 2 (37 participants): if \>= 11 non-progressions, Aplidin was considered promising.
Study: NCT01532050

Intervention type: DEVICE
Group type: OTHER
Intervention: Mandibular Advancement Device ( MAD)
Study: NCT05125861

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham remote ischemic conditioning
Description: Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.
Study: NCT00079937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: The omalizumab dose administered, based on the patient's body weight and total serum IgE level at Screening, and the number of injections and injection volume was determined from the dosing tables in the protocol. Omalizumab 75 to 375 mg was administered subcutaneous (SC) every 2 or 4 weeks depending on the dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) ≥ 200 μg/day equivalent of fluticasone administered with a dry-powder inhaler.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone
Description: Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) ≥ 200 μg/day equivalent of fluticasone administered with a dry-powder inhaler.
Study: NCT02582203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftaroline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin